Wells Fargo Maintains Overweight on AbbVie, Raises Price Target to $300

Benzinga · 2d ago
Wells Fargo analyst Mohit Bansal maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $295 to $300.